Acquired resistance in oncogene-addicted non-small-cell lung cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology 20(3), 370–378(2015).
  MedlineGoogle Scholar
• 2 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009). • Seminal paper demonstrating the utility of patient selection in non-small-cell lung cancer based on the molecular profile of the tumor.
  Medline CASGoogle Scholar
• 3 Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial. Lancet Oncol. 13(3), 239–246 (2012).
  Medline CASGoogle Scholar
• 4 Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327–3334 (2013).
  Medline CASGoogle Scholar
• 5 Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385–2394 (2013).
  Medline CASGoogle Scholar
• 6 Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011). •• First rebiopsy case series reporting in vivo the mechanisms of acquired resistance to first generation EGFR tyrosine kinase inhibitors.
  MedlineGoogle Scholar
• 7 Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
  MedlineGoogle Scholar
• 8 Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11(8), 473–481 (2014).
  Medline CASGoogle Scholar
• 9 Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18(5), 1472–1482 (2012).
  Medline CASGoogle Scholar
• 10 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 7(2), 137–155 (2017).
  Medline CASGoogle Scholar
• 11 Ballard P, Yates JW, Yang Z et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin. Cancer Res. 22(20), 5130–5140 (2016).
  Medline CASGoogle Scholar
• 12 Togashi Y, Masago K, Masuda S et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 70(3), 399–405 (2012).
  Medline CASGoogle Scholar
• 13 Russo A, Franchina T, Ricciardi GR et al. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Rev. Anticancer Ther. 16(6), 615–23 (2016).
  Medline CASGoogle Scholar
• 14 Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 20(9), 2249–2256 (2014).
  Medline CASGoogle Scholar
• 15 Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 6(294), re6 (2013).
  MedlineGoogle Scholar
• 16 Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19(8), 2240–2247 (2013).
  Medline CASGoogle Scholar
• 17 Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786–792 (2005).
  Medline CASGoogle Scholar
• 18 Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105(6), 2070–2075 (2008).
  Medline CASGoogle Scholar
• 19 Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102(21), 7665–7670 (2005).
  Medline CASGoogle Scholar
• 20 Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702–4711 (2008).
  Medline CASGoogle Scholar
• 21 Wu SG, Liu YN, Tsai MF et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 7(11), 12404–12413 (2016).
  MedlineGoogle Scholar
• 22 Sequist L, Wu YL, Schuler M et al. Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm1) NSCLC in LUX-Lung (LL) 3, 6 and 7. Ann. Oncol. 28(Suppl. 5), 482 (2017).
  Google Scholar
• 23 Turke AB, Zejnullahu K, Wu YL et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1), 77–88 (2010).
  Medline CASGoogle Scholar
• 24 Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039–1043 (2007).
  Medline CASGoogle Scholar
• 25 Takezawa K, Pirazzoli V, Arcila ME et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2(10), 922–933 (2012).
  Medline CASGoogle Scholar
• 26 Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene. 32(33), 3846–3856 (2013).
  Medline CASGoogle Scholar
• 27 Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109(31), E2127–E2133 (2012).
  Medline CASGoogle Scholar
• 28 Cortot AB, Repellin CE, Shimamura T et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 73(2), 834–843 (2013).
  Medline CASGoogle Scholar
• 29 Coco S, Truini A, Alama A et al. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Target Oncol. 10(3), 393–404 (2015).
  MedlineGoogle Scholar
• 30 Suda K, Tomizawa K, Fujii M et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 6(7), 1152–1161 (2011).
  MedlineGoogle Scholar
• 31 Lee JK, Lee J, Kim S et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 35(26), 3065–3074 (2017).
  Medline CASGoogle Scholar
• 32 Gandara DR, Li T, Lara PN et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin. Lung Cancer 15(1), 1–6 (2014).
  Medline CASGoogle Scholar
• 33 Chabon JJ, Simmons AD, Lovejoy AF et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun. 7, 11815 (2016). •• Seminal paper demonstrating the intrapatient heterogeneity of mechanisms of acquired resistance to both first/second generation tyrosine kinase inhibitors and mutant-selective inhibitors.
  Medline CASGoogle Scholar
• 34 Piotrowska Z, Niederst MJ, Karlovich CA et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5(7), 713–722 (2015). • Important paper demonstrating the intrapatient heterogeneity of mechanisms of acquired resistance mutant-selective inhibitors.
  Medline CASGoogle Scholar
• 35 Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin. Cancer Res. 17(1), 89–99 (2011).
  Medline CASGoogle Scholar
• 36 Weickhardt AJ, Scheier B, Burke JM et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol. 7(12), 1807–1814 (2012).
  Medline CASGoogle Scholar
• 37 Yu HA, Sima CS, Huang J et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 8(3), 346–351 (2013).
  Medline CASGoogle Scholar
• 38 Magnuson WJ, Lester-Coll NH, Wu AJ et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J. Clin. Oncol. 35(10), 1070–1077 (2017).
  Medline CASGoogle Scholar
• 39 Russo A, Franchina T, Ricciardi GRR et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit. Rev. Oncol. Hematol. 117, 38–47 (2017).
  Medline CASGoogle Scholar
• 40 Genova C, Rijavec E, Biello F et al. New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. Expert Opin. Pharmacother. 18(1), 19–33 (2017).
  Medline CASGoogle Scholar
• 41 Sequist LV, Soria JC, Goldman JW et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372(18), 1700–1709 (2015).
  MedlineGoogle Scholar
• 42 Park KM, Lee JS, Han JY et al. Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended Phase II dose. J. Thorac. Oncol. 11(Suppl. 4S), S113–S142 (2016).
  MedlineGoogle Scholar
• 43 Yang JC, Ahn MJ, Kim DW et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component. J. Clin. Oncol. 35(12), 1288–1296 (2017).
  Medline CASGoogle Scholar
• 44 Mok TS, Wu Y-L, Ahn M-J et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376(7), 629–640 (2017).
  Medline CASGoogle Scholar
• 45 Ramalingam SS, Yang JC, Lee CK et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell Lung Cancer. J. Clin. Oncol. 36(9), 841–849 (2017). • First comprehensive report of the mechanisms of acquired resistance to osimertinib after front-line use.
  MedlineGoogle Scholar
• 46 Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113–125 (2018).
  Medline CASGoogle Scholar
• 47 Wang S, Song Y, Liu D. EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 385, 51–54 (2017).
  Medline CASGoogle Scholar
• 48 Thress KS, Paweletz CP, Felip E et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21(6), 560–562 (2015).
  Medline CASGoogle Scholar
• 49 Bersanelli M, Minari R, Bordi P et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J. Thorac. Oncol. 11(10), e121–e123 (2016).
  MedlineGoogle Scholar
• 50 Ou SI, Cui J, Schrock AB et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 108, 228–231 (2017).
  MedlineGoogle Scholar
• 51 Knebel FH, Bettoni F, Shimada AK et al. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer 108, 238–241 (2017).
  MedlineGoogle Scholar
• 52 Planchard D, Loriot Y, André F et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 26(10), 2073–2078 (2015).
  Medline CASGoogle Scholar
• 53 Nukaga S, Yasuda H, Tsuchihara K et al. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 77(8), 2078–2089 (2017).
  Medline CASGoogle Scholar
• 54 Kim TM, Song A, Kim DW et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J. Thorac. Oncol. 10(12), 1736–1744 (2015).
  Medline CASGoogle Scholar
• 55 Ou SI, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer 98, 59–61 (2016).
  MedlineGoogle Scholar
• 56 Eberlein CA, Stetson D, Markovets AA et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 75(12), 2489–2500 (2015).
  Medline CASGoogle Scholar
• 57 Li L, Wang H, Li C, Wang Z, Zhang P, Yan X. Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report. Oncotarget 8(11), 18609–18614 (2017).
  MedlineGoogle Scholar
• 58 Oxnard GR, Paweletz CP, Sholl LM. Genomic analysis of plasma cell-free DNA in patients with cancer. JAMA Oncol. 3(6), 740–741 (2017).
  MedlineGoogle Scholar
• 59 Fenizia F, De Luca A, Pasquale R et al. EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol. 11(11), 1611–1623 (2015).
  CASGoogle Scholar
• 60 Krishnamurthy N, Spencer E, Torkamani A, Nicholson L. Liquid biopsies for cancer: coming to a patient near you. J. Clin. Med. 6(1), 3 (2017).
  Google Scholar
• 61 Cheng X, Chen H. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco. Targets Ther. 7, 1689–1704 (2014).
  Medline CASGoogle Scholar
• 62 Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J. Clin. Oncol. 31(8), 1039–1049 (2013).
  Medline CASGoogle Scholar
• 63 Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32(6), 579–586 (2014).
  MedlineGoogle Scholar
• 64 Goto K, Ichinose Y, Ohe Y et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a Phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J. Thorac. Oncol. 7(1), 115–121 (2012).
  Medline CASGoogle Scholar
• 65 Luke JJ, Oxnard GR, Paweletz CP et al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J. Natl Cancer Inst. 106(8), (2014).
  MedlineGoogle Scholar
• 66 Martín Martorell P, Huerta M, Compañ Quilis A et al. Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish nonsquamous NSCLC patients. Clin. Lung Cancer 18(6), e395–e402 (2017).
  MedlineGoogle Scholar
• 67 Li BS, Wang XY, Xu AG et al. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA test for the detection of mutations in colorectal neoplasms. Clin. Colorectal Cancer. 11(4), 280–290 (2012).
  MedlineGoogle Scholar
• 68 Guha M, Castellanos-Rizaldos E, Makrigiorgos GM. DISSECT method using PNA-LNA Clamp improves detection of EGFR T790m mutation. PLoS ONE 8(6), e67782 (2013).
  Medline CASGoogle Scholar
• 69 Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat. Med. 14(5), 579–84 (2008).
  Medline CASGoogle Scholar
• 70 Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734–1739 (2010).
  Medline CASGoogle Scholar
• 71 Lucena-Araujo AR, Moran JP, VanderLaan PA et al. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer 99, 17–22 (2016).
  MedlineGoogle Scholar
• 72 Shaw AT, Friboulet L, Leshchiner I et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374(1), 54–61 (2016).
  Medline CASGoogle Scholar
• 73 Gainor JF, Dardaei L, Yoda S et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6(10), 1118–1133 (2016). •• Seminal work on the in vivo mechanisms of acquired resistance to different class of anaplastic lymphoma kinase inhibitors.
  Medline CASGoogle Scholar
• 74 Ignatius Ou SH, Azada M, Hsiang DJ et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J. Thorac. Oncol. 9(4), 549–553 (2014).
  Medline CASGoogle Scholar
• 75 Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71(18), 6051–6060 (2011).
  Medline CASGoogle Scholar
• 76 Kodityal S, Elvin JA, Squillace R et al. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Lung Cancer 92, 19–21 (2016).
  MedlineGoogle Scholar
• 77 Katayama R, Friboulet L, Koike S et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20(22), 5686–5696 (2014).
  Medline CASGoogle Scholar
• 78 Toyokawa G, Inamasu E, Shimamatsu S et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib. J. Thorac. Oncol. 10(7), e55–e57 (2015).
  MedlineGoogle Scholar
• 79 Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4(120), 120ra17 (2012).
  MedlineGoogle Scholar
• 80 Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18(5), 1472–1482 (2012).
  Medline CASGoogle Scholar
• 81 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 7(2), 137–155 (2017).
  Medline CASGoogle Scholar
• 82 Shaw AT, Kim TM, Crinò L et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, Phase III trial. Lancet Oncol. 18(7), 874–886 (2017).
  Medline CASGoogle Scholar
• 83 de Castro J, Novello S, Mazieres J et al. CNS efficacy results from the Phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC. Ann. Oncol. 28(Suppl. 5), 481 (Abstract 1346P) (2017).
  Google Scholar
• 84 Novello S, Mazieres J, Oh I et al. Primary results from the Phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann. Oncol. 28(suppl_5), v605–v649 (2017).
  Google Scholar
• 85 Gettinger SN, Bazhenova LA, Langer CJ et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, Phase I/II trial. Lancet Oncol. 17(12), 1683–1696 (2016).
  Medline CASGoogle Scholar
• 86 Yang JC, Ou SI, De Petris L et al. Pooled systemic efficacy and safety data from the pivotal Phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer. J. Thorac. Oncol. 12(10), 1552–1560 (2017).
  MedlineGoogle Scholar
• 87 Kim DW, Tiseo M, Ahn MJ et al. Brigatinib in patients With crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter Phase II trial. J. Clin. Oncol. 35(22), 2490–2498 (2017).
  Medline CASGoogle Scholar
• 88 Kim DW, Mehra R, Tan DS et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, Phase I trial. Lancet Oncol. 17(4), 452–463 (2016).
  Medline CASGoogle Scholar
• 89 Gandhi L, Ou SI, Shaw AT et al. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria. Eur. J. Cancer 82, 27–33 (2017).
  Medline CASGoogle Scholar
• 90 Landi L, Cappuzzo F. Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. Transl. Lung Cancer Res. 5(6), 579–587 (2016).
  Medline CASGoogle Scholar
• 91 Shaw AT, Gandhi L, Gadgeel S et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, Phase II trial. Lancet Oncol. 17(2), 234–242 (2016).
  Medline CASGoogle Scholar
• 92 Ou SH, Ahn JS, De Petris L et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II global study. J. Clin. Oncol. 34(7), 661–668 (2016).
  Medline CASGoogle Scholar
• 93 Crinò L, Ahn MJ, De Marinis F et al. Multicenter Phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J. Clin. Oncol. 34(24), 2866–2873 (2016).
  Medline CASGoogle Scholar
• 94 Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377(9), 829–838 (2017).
  Medline CASGoogle Scholar
• 95 Hida T, Nokihara H, Kondo M et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised Phase III trial. Lancet 390(10089), 29–39 (2017).
  Medline CASGoogle Scholar
• 96 Soria JC, Tan DSW, Chiari R et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, Phase III study. Lancet 389 (10072), 917–929 (2017).
  Medline CASGoogle Scholar
• 97 Gainor JF, Tan DS, De Pas T et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin. Cancer Res. 21(12), 2745–2752 (2015).
  Medline CASGoogle Scholar
• 98 Woo CG, Seo S, Kim SW et al. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann. Oncol. 28(4), 791–797 (2017).
  Medline CASGoogle Scholar
• 99 Lin JJ, Zhu VW, Yoda S et al. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J. Clin. Oncol. doi: 10.1200/JCO.2017.76.2294 (2018) (Epub ahead of print).
  Google Scholar
• 100 Kim S, Kim TM, Kim DW et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 8(4), 415–422 (2013).
  Medline CASGoogle Scholar
• 101 Crystal AS, Shaw AT, Sequist LV et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346 (6216), 1480–1486 (2014).
  Medline CASGoogle Scholar
• 102 Hrustanovic G, Olivas V, Pazarentzos E et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21(9), 1038–1047 (2015).
  Medline CASGoogle Scholar
• 103 Miyawaki M, Yasuda H, Tani T et al. Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer. Mol. Cancer Res. 15(1), 106–114 (2017).
  Medline CASGoogle Scholar
• 104 Lovly CM, McDonald NT, Chen H et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 20(9), 1027–1034 (2014).
  Medline CASGoogle Scholar
• 105 Wilson FH, Johannessen CM, Piccioni F et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27(3), 397–408 (2015).
  Medline CASGoogle Scholar
• 106 Bazhenova L, Hodgson JG, Langer CJ et al. Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status. J. Clin. Oncol. 35, (suppl), abstr 9065 (2017).
  Google Scholar
• 107 Toyokawa G, Hirai F, Inamasu E et al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J. Thorac. Oncol. 9(12), e86–e87 (2014).
  MedlineGoogle Scholar
• 108 Takegawa N, Hayashi H, Iizuka N et al. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann. Oncol. 27(5), 953–955 (2016).
  Medline CASGoogle Scholar
• 109 Ou SI, Lee TK, Young L et al. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer 106, 110–114 (2017).
  MedlineGoogle Scholar
• 110 Levacq D, D'Haene N, de Wind R, Remmelink M, Berghmans T. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors. Lung Cancer 102:38–41 (2016).
  MedlineGoogle Scholar
• 111 Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J. Thorac. Oncol. 11(6), e67–e72 (2016).
  MedlineGoogle Scholar
• 112 Cha YJ, Cho BC, Kim HR, Lee HJ, Shim HS. A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib. J. Thorac. Oncol. 11(5), e55–e58 (2016).
  MedlineGoogle Scholar
• 113 Rolfo CD, Laes JF, Reclusa P et al. Liquid biopsy analysis of ALK alterations from advanced NSCLC patients: the value of exosomal RNA cargo (ExoALK). J. Clin. Oncol. 35(Suppl.), Abstract e20569 (2017).
  MedlineGoogle Scholar